Arcus Biosciences EBITDA 2017-2023 | RCUS
Arcus Biosciences ebitda from 2017 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Arcus Biosciences Annual EBITDA
(Millions of US $) |
| 2022 |
$-274 |
| 2021 |
$63 |
| 2020 |
$-121 |
| 2019 |
$-88 |
| 2018 |
$-53 |
| 2017 |
$-51 |
| 2016 |
$-17 |
Arcus Biosciences Quarterly EBITDA
(Millions of US $) |
| 2023-03-31 |
$-88 |
| 2022-12-31 |
$-75 |
| 2022-09-30 |
$-68 |
| 2022-06-30 |
$-67 |
| 2022-03-31 |
$-64 |
| 2021-12-31 |
$285 |
| 2021-09-30 |
$-76 |
| 2021-06-30 |
$-74 |
| 2021-03-31 |
$-71 |
| 2020-12-31 |
$-51 |
| 2020-09-30 |
$3 |
| 2020-06-30 |
$-45 |
| 2020-03-31 |
$-28 |
| 2019-12-31 |
$-17 |
| 2019-09-30 |
$-23 |
| 2019-06-30 |
$-29 |
| 2019-03-31 |
$-19 |
| 2018-12-31 |
$-13 |
| 2018-09-30 |
$-12 |
| 2018-06-30 |
$-15 |
| 2018-03-31 |
$-13 |
| 2017-12-31 |
$-13 |
| 2017-09-30 |
$-22 |
| 2017-06-30 |
$-9 |
| 2017-03-31 |
$-7 |
| 2016-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.536B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
